Affordable Access

Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches.

Authors
  • Kipps, T J
Type
Published Article
Journal
Seminars in Hematology
Publisher
Elsevier - WB Saunders
Publication Date
Oct 01, 1999
Volume
36
Issue
4 Suppl 5
Pages
3–8
Identifiers
PMID: 10528909
Source
Medline
License
Unknown

Abstract

Cancer is a genetic disease caused by somatic mutation(s) in essential genes that regulate cell growth or survival. Advances in genetics have identified molecular defects that can be targeted by novel pharmaceutics that exploit the altered genetic machinery of tumor cells. Gene transfer also can be used to potentiate the host immune response to weak tumor antigens that may arise during the process of neoplastic transformation. Advances in our understanding of the mechanics of immune activation have led to development of immune-based strategies for gene therapy of cancer. Preliminary findings in a phase I trial of one such approach in patients with chronic lymphocytic leukemia (CLL) are encouraging. Conceivably, we soon may see the advent of effective gene therapy for patients with indolent B-cell malignancies.

Report this publication

Statistics

Seen <100 times